We are live on ! Find out more
PAHC icon

Phibro Animal Health

147 hedge funds and large institutions have $457M invested in Phibro Animal Health in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 49 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

35% more capital invested

Capital invested by funds: $337M → $457M (+$119M)

18% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 49

4% more funds holding

Funds holding: 141147 (+6)

0.83% more ownership

Funds ownership: 98.91%99.74% (+0.83%)

Holders
147
Holders Change
+6
Holders Change %
+4.26%
% of All Funds
2.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
58
Reduced
49
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$80.8M +$1.62M +84,033 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$33.6M +$2.52M +130,258 +10%
BIP
3
Brandes Investment Partners
California
$33.4M -$17.8M -920,890 -38%
Pzena Investment Management
4
Pzena Investment Management
New York
$32.9M -$7.26M -376,206 -20%
State Street
5
State Street
Massachusetts
$20.4M -$643K -33,324 -4%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$17.5M +$44.5K +2,305 +0.3%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$16.2M +$15.7K +811 +0.1%
PL
8
Parkwood LLC
Ohio
$12.5M +$10.7M +554,251 New
Renaissance Technologies
9
Renaissance Technologies
New York
$12.3M +$394K +20,400 +4%
American Century Companies
10
American Century Companies
Missouri
$12.1M +$3.7M +191,621 +55%
Morgan Stanley
11
Morgan Stanley
New York
$12M +$1.64M +84,964 +19%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$11.4M +$525K +27,201 +6%
N
13
Nuveen
North Carolina
$10.9M +$2.66M +137,773 +40%
DIA
14
Dana Investment Advisors
Wisconsin
$10.4M -$1.04M -54,103 -11%
CM
15
CastleKnight Management
New York
$8.26M +$2.28M +118,000 +47%
Goldman Sachs
16
Goldman Sachs
New York
$7.73M +$2.25M +116,334 +51%
Charles Schwab
17
Charles Schwab
California
$6.04M +$8.23K +426 +0.2%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$5.97M +$349K +18,067 +7%
AQR Capital Management
19
AQR Capital Management
Connecticut
$5.77M +$1.41M +73,058 +40%
SI
20
Sofinnova Investments
California
$5.36M +$22.7K +1,175 +0.5%
Arrowstreet Capital
21
Arrowstreet Capital
Massachusetts
$5.35M +$1.65M +85,636 +56%
Invesco
22
Invesco
Georgia
$5.28M -$1.07M -55,345 -19%
Northern Trust
23
Northern Trust
Illinois
$5.15M +$68K +3,520 +2%
GC
24
Globeflex Capital
California
$4.61M +$3.16M +163,557 +396%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$4.33M +$2M +103,491 +117%

PAHC Hedge Fund Activity: Q3 2024 in Review

147 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Phibro Animal Health (PAHC) for Q3 2024, worth a combined $457M — up 35% from $337M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PAHC positions and 14 closed out — a net gain of 6 holders — while 58 added to existing stakes and 49 trimmed.

The largest buyer was Parkwood LLC, opening a new position worth an estimated $10.7M. The largest seller was Brandes Investment Partners, cutting an estimated $17.8M.

  • 147 institutional investors held Phibro Animal Health (PAHC) as of Q3 2024, up from 141 in Q2 2024.
  • Funds reported $457M of Phibro Animal Health stock for Q3 2024, up 35% quarter-over-quarter.
  • 20 funds opened new Phibro Animal Health positions in Q3 2024 and 14 closed out, a net change of +6 holders.
  • The largest Phibro Animal Health buyer in Q3 2024 was Parkwood LLC, an estimated $10.7M added.
  • The largest Phibro Animal Health seller in Q3 2024 was Brandes Investment Partners, an estimated $17.8M sold.

Based on aggregated 13F filings for Q3 2024.